Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials

Clinical trial results indicate that brentuximab vedotin brings considerable promise for the treatment of patients with relapsed or refractory Hodgkin’s lymphoma. A retrospective multicenter study was conducted on 65 heavily pretreated patients who underwent therapy through a Named Patient Program i...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Zinzani, Pier Luigi, Viviani, Simonetta, Anastasia, Antonella, Vitolo, Umberto, Luminari, Stefano, Zaja, Francesco, Corradini, Paolo, Spina, Michele, Brusamolino, Ercole, Gianni, Alessandro M., Santoro, Armando, Botto, Barbara, Derenzini, Enrico, Pellegrini, Cinzia, Argnani, Lisa
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Ferrata Storti Foundation 2013
Θέματα:
Original Articles and Brief Reports
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3729903/
https://ncbi.nlm.nih.gov/pubmed/23645687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.083048
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια